COL4A5 and chronic kidney disease: Both prophylactic and therapeutic tamoxifen treatments led to significant reductions in plasma cholesterol levels, further supporting the therapeutic benefit of Col4a5 exon 21 skipping in ameliorating the systemic consequences of proteinuria and CKD (Fig. 3D).